Skip to main content

Find Drugs & Conditions

Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.

FDA Approves Fabhalta (iptacopan) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Basel, December 6, 2023 — Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first...

Earlier Age at Menarche Raises Type 2 Diabetes Risk

Earlier age at menarche is associated with type 2 diabetes risk among women younger than 65 years, according to a study published online Dec. 5 in BMJ...

Nonagenarians Are Mostly Sedentary, With Low Physical Activity

Nonagenarians are mostly sedentary and report low physical activity, according to a study published online Dec. 6 in PLOS ONE.Sari Aaltonen, Ph.D., from...

Housing Instability Tied to Higher Risk for Dementia Diagnosis

Veterans experiencing housing instability have a substantially higher risk for receiving an Alzheimer disease or related dementia (ADRD) diagnosis versus...

Many Patients of Color Expect and Prepare for Unfair Health Care

Minorities often feel a deep sense of dread before doctor appointments, and some even try to dress especially well for their visit to try and ward off...

New Weight-Loss Drug Zepbound Is Now Available, Company Says

The newly approved weight-loss medication known as Zepbound is now available for patients to take, drug maker Eli Lilly announced Tuesday. "Today opens...

As One Spouse's Blood Pressure Rises, So Does the Other's: Study

In sickness and in health -- and in blood pressure, too? A new international study finds that if your blood pressure rises with time, your spouse's might,...

State Abortion Bans Have New Doctors Staying Away

States that ban abortion could be headed to a brain drain when it comes to up-and-coming medical professionals. Three out of four future U.S. doctors...

Women Need Better Guidance on Exercise & the Menstrual Cycle, Study Shows

“Cycle syncing” – the notion that women should adapt their diet and exercise patterns to their menstrual cycle – has become a trendy...

Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors

WALTHAM, Mass., Dec. 5, 2023. Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced it...

Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China

SHANGHAI, Dec. 3, 2023. Everest Medicines ("Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization...

Your Personality Might Help Shield You From Dementia

Got a naturally sunny disposition? It might protect you from dementia as the years advance, new research shows. A team at Northwestern University in Chicago...

Monthly News Roundup - November 2023

FDA Approves Lilly’s Zepbound for Chronic Weight Management In November, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s...

Read more news...

Recently Added

Recently added consumer and prescribing information: Ogsiveo, DefenCath, Adzynma, Zituvimet, Voquezna, Combogesic IV, Omvoh, Zymfentra, Cabtreo, Tofidence

For Consumers

For Professionals

For Researchers

Latest FDA New Drug Approvals

  • Fabhalta Iptacopan is a first-in-class, oral factor B inhibitor in development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
  • Ogsiveo Ogsiveo (nirogacestat) is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment.
  • Ryzneuta Ryzneuta (efbemalenograstim alfa-vuxw) is a leukocyte growth factor to used to reduce the duration of febrile neutropenia in patients...

More FDA approvals

Drugs in Development (Not yet approved)

  • Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) to...
  • Libervant Libervant (diazepam) is a buccal film formulation of the approved benzodiazepine diazepam in development for the management of seizure clusters.

More drugs in development